Sarepta Therapeutics (SRPT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $17.10, -3.88% vs the prior close of $17.79.
- Volume 9.86M shares, 3.3x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SRPT slides 3.9% to $17.10 on 3.3x normal volume. Closed at $17.10, -3.88% vs the prior close of $17.79. Day range $16.88–$17.84, opened at $17.82.
SRPT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SRPT slides 3.9% to $17.10 on 3.3x normal volume
- Closed at $17.10, -3.88% vs the prior close of $17.79. Day range $16.88–$17.84, opened at $17.82.
- Volume was 9.86M shares, 3.3x its 50-day average of 2.97M — unusually heavy trading.
- Price is -10.8% vs its 50-day average ($19.18) and -9.6% vs its 200-day average ($18.91).
- 52-week range $14.68–$24.68; today's close sits at 24% of that range, 30.7% below the 52-week high.
Oct 15, 2026 — SRPT jumps 5.7% to $17.79
- Closed at $17.79, +5.70% vs the prior close of $16.83. Day range $16.61–$17.96, opened at $16.96.
- Volume was 4.04M shares, 1.4x its 50-day average of 2.95M.
- Price is -7.2% vs its 50-day average ($19.17) and -6.0% vs its 200-day average ($18.93).
- 52-week range $14.68–$24.68; today's close sits at 31% of that range, 27.9% below the 52-week high.
Oct 14, 2026 — SRPT rises 1.9% to $16.83
- Closed at $16.83, +1.94% vs the prior close of $16.51. Day range $16.37–$16.91, opened at $16.53.
- Volume was 2.74M shares, 0.9x its 50-day average of 2.95M.
- Price is -12.0% vs its 50-day average ($19.13) and -11.2% vs its 200-day average ($18.95).
- 52-week range $14.68–$24.68; today's close sits at 21% of that range, 31.8% below the 52-week high.
Oct 13, 2026 — SRPT slides 5.3% to $16.51, a 1-month low, 3 down days in a row
- Closed at $16.51, -5.33% vs the prior close of $17.44. Day range $16.41–$17.23, opened at $17.12.
- Volume was 3.68M shares, 1.2x its 50-day average of 2.95M.
- Price is -13.7% vs its 50-day average ($19.12) and -13.0% vs its 200-day average ($18.98).
- 52-week range $14.68–$24.68; today's close sits at 18% of that range, 33.1% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — SRPT dips 2.3% to $17.44
- Closed at $17.44, -2.30% vs the prior close of $17.85. Day range $17.30–$18.14, opened at $17.88.
- Volume was 3.28M shares, 1.1x its 50-day average of 2.96M.
- Price is -8.8% vs its 50-day average ($19.11) and -8.2% vs its 200-day average ($19.00).
- 52-week range $14.68–$24.68; today's close sits at 28% of that range, 29.3% below the 52-week high.
Oct 9, 2026 — SRPT dips 2.0% to $17.85
- Closed at $17.85, -1.98% vs the prior close of $18.21. Day range $17.68–$18.53, opened at $18.25.
- Volume was 3.01M shares, 1.0x its 50-day average of 2.96M.
- Price is -6.4% vs its 50-day average ($19.06) and -6.2% vs its 200-day average ($19.03).
- 52-week range $14.68–$24.68; today's close sits at 32% of that range, 27.7% below the 52-week high.
Oct 8, 2026 — SRPT jumps 4.1% to $18.21
- Closed at $18.21, +4.06% vs the prior close of $17.50. Day range $17.20–$18.28, opened at $17.28.
- Volume was 3.52M shares, 1.2x its 50-day average of 2.95M.
- Price is -4.2% vs its 50-day average ($19.01) and -4.4% vs its 200-day average ($19.04).
- 52-week range $14.68–$25.32; today's close sits at 33% of that range, 28.1% below the 52-week high.
Oct 7, 2026 — SRPT rises 1.1% to $17.50
- Closed at $17.50, +1.10% vs the prior close of $17.31. Day range $16.98–$17.67, opened at $17.28.
- Volume was 2.87M shares, 1.0x its 50-day average of 2.96M.
- Price is -7.7% vs its 50-day average ($18.96) and -8.2% vs its 200-day average ($19.06).
- 52-week range $14.68–$25.32; today's close sits at 27% of that range, 30.9% below the 52-week high.
Oct 6, 2026 — SRPT dips 1.0% to $17.31, a 1-month low, 6 down days in a row
- Closed at $17.31, -1.03% vs the prior close of $17.49. Day range $17.04–$17.65, opened at $17.60.
- Volume was 2.69M shares, 0.9x its 50-day average of 2.98M.
- Price is -8.5% vs its 50-day average ($18.92) and -9.2% vs its 200-day average ($19.07).
- 52-week range $14.68–$25.32; today's close sits at 25% of that range, 31.6% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — SRPT ends flat (-0.1%) to $17.49, a 1-month low, 5 down days in a row
- Closed at $17.49, -0.06% vs the prior close of $17.50. Day range $17.10–$17.55, opened at $17.39.
- Volume was 2.20M shares, 0.7x its 50-day average of 2.98M.
- Price is -7.4% vs its 50-day average ($18.89) and -8.4% vs its 200-day average ($19.09).
- 52-week range $14.68–$25.32; today's close sits at 26% of that range, 30.9% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — SRPT dips 0.4% to $17.50, a 1-month low, 4 down days in a row
- Closed at $17.50, -0.40% vs the prior close of $17.57. Day range $17.21–$17.76, opened at $17.75.
- Volume was 2.55M shares, 0.9x its 50-day average of 2.98M.
- Price is -7.2% vs its 50-day average ($18.86) and -8.5% vs its 200-day average ($19.12).
- 52-week range $14.68–$25.32; today's close sits at 27% of that range, 30.9% below the 52-week high.
- That makes 4 straight losses.
SRPT latest news & SEC filings
Every SEC filing by or about SRPT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form 13F-HR — Quarterly holdings report filed by an institutional investment manager
Quarterly holdings report filed by an institutional investment manager
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $328.69M (prior year $513.12M) (-35.9% vs Jun 30, 2025)
- Net income: -$4.89M (prior year $196.89M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.05 (prior year $1.89) (loss widened vs Jun 30, 2025)
Jul 31, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 28, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade SRPT
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 25, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.60% (largest 8.9%).
- Liquidity: about 3.07M shares (≈$52.54M) trade per day on average.
- 52-week position: $17.10 vs a range of $14.68–$24.68 (24% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 8 sales; latest: Stephen Mayo sold 7,239 shares on Mar 12, 2026.
- Latest filings: 8-K Aug 5, 2026; 10-Q Aug 5, 2026; 8-K Jul 27, 2026.
- Share count: 105.63M shares outstanding (Jul 31, 2026), +8.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SRPT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 17.82 | 17.84 | 16.88 | 17.10 | 9.86M |
| Oct 15, 2026 | 16.96 | 17.96 | 16.61 | 17.79 | 4.04M |
| Oct 14, 2026 | 16.53 | 16.91 | 16.37 | 16.83 | 2.74M |
| Oct 13, 2026 | 17.12 | 17.23 | 16.41 | 16.51 | 3.68M |
| Oct 12, 2026 | 17.88 | 18.14 | 17.30 | 17.44 | 3.28M |
| Oct 9, 2026 | 18.25 | 18.53 | 17.68 | 17.85 | 3.01M |
| Oct 8, 2026 | 17.28 | 18.28 | 17.20 | 18.21 | 3.52M |
| Oct 7, 2026 | 17.28 | 17.67 | 16.98 | 17.50 | 2.87M |
| Oct 6, 2026 | 17.60 | 17.65 | 17.04 | 17.31 | 2.69M |
| Oct 5, 2026 | 17.39 | 17.55 | 17.10 | 17.49 | 2.20M |
| Oct 2, 2026 | 17.75 | 17.76 | 17.21 | 17.50 | 2.55M |
| Oct 1, 2026 | 18.14 | 18.25 | 17.52 | 17.57 | 2.88M |
| Sep 30, 2026 | 18.64 | 18.69 | 18.06 | 18.22 | 2.00M |
| Sep 29, 2026 | 18.68 | 18.74 | 18.38 | 18.64 | 1.37M |
| Sep 28, 2026 | 18.43 | 18.86 | 17.64 | 18.80 | 2.27M |
| Sep 25, 2026 | 18.49 | 18.77 | 18.02 | 18.67 | 2.22M |
| Sep 24, 2026 | 18.85 | 19.14 | 18.05 | 18.39 | 2.56M |
| Sep 23, 2026 | 20.72 | 20.76 | 18.74 | 18.95 | 3.76M |
| Sep 22, 2026 | 20.46 | 21.19 | 20.19 | 20.81 | 2.19M |
| Sep 21, 2026 | 20.29 | 20.50 | 19.97 | 20.14 | 1.76M |
About Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 873303.
SRPT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| M Kathleen Behrens | Director | Jun 5, 2026 |
| Richard Barry | Director | Jun 5, 2026 |
| Kathryn Jean Boor | Director | Jun 5, 2026 |
| Michael Andrew Chambers | Director | Jun 5, 2026 |
| Deirdre P Connelly | Director | Jun 5, 2026 |
| Douglas S Ingram | Chief Executive Officer | Dec 9, 2025 |
| Stephen Mayo | Director | Jun 5, 2026 |
| Claude Nicaise | Director | Jun 5, 2026 |
| Michael Severino | Chief Executive Officer | Jul 29, 2026 |
| Hans Lennart Rudolf Wigzell | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ian Michael Estepan | Chief Operating Officer | Sep 8, 2026 |
| Douglas S Ingram | Chief Executive Officer | Dec 9, 2025 |
| Louise Rodino-Klapac | President, R&D and Tech Ops | Sep 8, 2026 |
| Cristin Rothfuss | EVP, General Counsel | Sep 8, 2026 |
| Michael Severino | Chief Executive Officer | Jul 29, 2026 |
| Ryan Ho-Yan Wong | Chief Financial Officer | Sep 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 12, 2026 | Stephen Mayo | Sale | 7,239 | $17.02 |
| Mar 12, 2026 | Stephen Mayo | Sale | 7,239 | $17.02 |
| Mar 12, 2026 | Stephen Mayo | Sale | 7,239 | $17.02 |
| Mar 12, 2026 | Stephen Mayo | Sale | 7,239 | $17.02 |
| Dec 16, 2025 | Ian Michael Estepan | Sale | 13,187 | $22.31 |
| Dec 16, 2025 | Ian Michael Estepan | Sale | 13,187 | $22.31 |
| Dec 16, 2025 | Ian Michael Estepan | Sale | 13,187 | $22.31 |
| Dec 16, 2025 | Ian Michael Estepan | Sale | 13,187 | $22.31 |
SRPT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.86B | $-713.41M | -7.13 | $-205.48M |
| Dec 31, 2024 | $1.79B | $235.24M | 2.34 | $-205.79M |
| Dec 31, 2023 | $1.14B | $-535.98M | -5.80 | $-500.99M |
| Dec 31, 2022 | $843.77M | $-703.49M | -8.03 | $-325.35M |
| Dec 31, 2021 | $612.40M | $-418.78M | -5.15 | $-443.17M |
Latest balance sheet: total assets $3.19B, total liabilities $1.66B, cash $571.15M (as of Jun 30, 2026).
SRPT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $15.93 |
| May 6, 2026 | 8-K Item 2.02 (results) | $23.03 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $18.97 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $21.14 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $24.45 |
| Jul 16, 2025 | 8-K Item 2.02 (results) | $18.38 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $106.86 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $118.43 |
| Jan 8, 2024 | 8-K Item 2.02 (results) | — |
| Jan 9, 2023 | 8-K Item 2.02 (results) | — |
| Jan 10, 2022 | 8-K Item 2.02 (results) | — |
| Oct 15, 2021 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SRPT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.